Why Merck Missed the Mark

Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold

Click here for reuse options!
Copyright 2003 Biotechblog

Leave a Reply

%d bloggers like this: